Retatrutide vs Zepbound (2026): Pipeline Drug vs FDA-Approved
Retatrutide (retatrutide (LY3437943), Eli Lilly) vs Zepbound (tirzepatide, Eli Lilly)
Last verified 2026-07-06
The verdict
Retatrutide (LY3437943) and Zepbound (tirzepatide) are both developed by Eli Lilly, but they sit at opposite ends of the regulatory spectrum: Zepbound is FDA-approved and commercially available for chronic weight management, while retatrutide is an investigational triple agonist still completing Phase 3 TRIUMPH trials. Cross-trial comparison suggests retatrutide may produce somewhat greater weight loss — 24.2% at 48 weeks in Phase 2 (12 mg; N=81 in that arm) versus Zepbound's 20.9% at 72 weeks in SURMOUNT-1 (15 mg; N=630 in that arm) — but this comparison carries a critical caveat: retatrutide's figure comes from a small Phase 2 trial with shorter follow-up, whereas Zepbound's comes from a large, definitive Phase 3 trial. Phase 2 efficacy signals frequently attenuate in larger Phase 3 trials. Until TRIUMPH data are published, no superiority claim for retatrutide is warranted. For patients who need treatment today, Zepbound is the only evidence-backed and legally obtainable option.
Side-by-side comparison
| Field | Retatrutide | Zepbound |
|---|---|---|
| Peak weight loss (trial) | −24.2% at 48 wk (Phase 2, 12 mg; N=81 in highest-dose arm) | −20.9% at 72 wk (SURMOUNT-1, 15 mg; Phase 3, N=630 in that arm) |
| Mechanism | Triple agonist: GLP-1, GIP, and glucagon receptors | Dual agonist: GLP-1 and GIP receptors |
| FDA status | Not FDA-approved; TRIUMPH Phase 3 trials ongoing | FDA approved November 2023 for chronic weight management in adults |
| Trial stage | Phase 3 (TRIUMPH program; results expected 2026–2027) | Phase 3 complete (SURMOUNT program); full regulatory approval granted |
| Availability | Not available; accessible through TRIUMPH clinical trials (clinicaltrials.gov) only | Commercially available by prescription in the United States |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection (2.5 mg–15 mg titrated dose) |
| GI side effects | Dose-related nausea, vomiting, diarrhea; mostly mild–moderate in Phase 2; dose-dependent heart rate increase (peaked wk 24, declined thereafter) | Nausea, vomiting, diarrhea, constipation; mild–moderate, mainly during dose escalation; discontinuation rate 4.3–7.1% |
Frequently asked questions
Is retatrutide better than Zepbound for weight loss?
Retatrutide's Phase 2 data (−24.2% at 48 weeks, 12 mg) numerically exceeded Zepbound's Phase 3 results (−20.9% at 72 weeks, 15 mg), but a direct head-to-head trial does not exist. Phase 2 trials often overestimate real-world efficacy compared to larger Phase 3 trials, and the retatrutide comparison arm was small (N=81). TRIUMPH Phase 3 results are needed before any superiority claim is justified.
When will retatrutide be available?
Retatrutide is completing Phase 3 TRIUMPH trials as of 2026. If results are positive, Eli Lilly may file an NDA in 2027, with a possible market launch in 2027–2028. It is currently accessible only through registered clinical trials — search clinicaltrials.gov for TRIUMPH study listings.
Can I switch from Zepbound to retatrutide?
Not outside of a clinical trial. Retatrutide is not FDA-approved as of mid-2026. If you are responding well to Zepbound, continuing treatment is recommended. Discuss TRIUMPH trial eligibility with your doctor if you are interested in accessing retatrutide experimentally.
Why did Eli Lilly develop retatrutide if they already have Zepbound?
Retatrutide adds glucagon receptor agonism to the GLP-1 + GIP dual mechanism in tirzepatide (Zepbound). Glucagon signaling may increase energy expenditure beyond what dual agonism achieves, potentially pushing weight loss above 25–30%. Eli Lilly is developing retatrutide as a potential next-generation therapy for patients who need greater efficacy.
Does retatrutide work for type 2 diabetes like Zepbound (Mounjaro)?
Zepbound (tirzepatide) is also FDA-approved as Mounjaro for type 2 diabetes. Retatrutide's glucagon receptor activity theoretically could raise blood glucose in some patients, a concern that is being evaluated in Phase 3. Phase 2 data showed favorable glycemic effects overall. For T2D today, Mounjaro/Zepbound is the proven and approved choice.
What are the side effects of retatrutide compared to Zepbound?
Both drugs share GLP-1-related GI side effects: nausea, vomiting, diarrhea, and constipation. In retatrutide's Phase 2 trial, these were dose-related and mostly mild to moderate, and were partially mitigated by a lower starting dose (2 mg versus 4 mg). Retatrutide also caused dose-dependent heart rate increases that peaked at week 24 and declined — a pattern seen with other incretins. The full safety profile will not be established until Phase 3 is complete.
References
- 1.Jastreboff AM, Kaplan LM, Frías JP, et al.; Retatrutide Phase 2 Obesity Trial Investigators Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial N Engl J Med. 2023. PMID: 37366315.
- 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med. 2022. PMID: 35658024.
- 3.Giblin K, Bethel MA, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Diabetes Obes Metab. 2026. PMID: 41090431.
Related comparisons
- Wegovy vs Zepbound
- Ozempic vs Mounjaro
- Semaglutide vs Tirzepatide
- Rybelsus vs Ozempic
- Mounjaro vs Zepbound
- Foundayo vs Rybelsus
See the full drug-vs-drug verdict index or provider rankings.